Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis - PubMed
7 hours ago
- #elotuzumab
- #multiple myeloma
- #adverse events
- Elotuzumab, an anti-SLAMF7 monoclonal antibody, was evaluated for its safety profile in multiple myeloma (MM) patients.
- A meta-analysis of 6 randomized controlled trials (RCTs) involving 1,736 patients was conducted.
- Elotuzumab reduced the incidence of neutropenia but increased risks of cough, pneumonia, diarrhea, pyrexia, and infections.
- No significant differences were found for anemia, thrombocytopenia, respiratory infections, nausea, and other common side effects.
- For grade 3-4 adverse events, elotuzumab was linked to higher risks of lymphopenia, diarrhea, pneumonia, cataracts, and infections.
- The study concludes that elotuzumab is generally safe but has a specific pattern of adverse events, including respiratory, gastrointestinal, metabolic, and infectious risks.
- Longer treatment duration and corticosteroid use may influence outcomes like hyperglycemia and cataracts, requiring cautious interpretation.